Abstract
The aim of this paper is to review the latest data on the pharmacological modulation of asymmetric dimethylarginine in human disease. When the terminal nitrogens of the guanidine portion of an arginine become methylated through the action of N-methyl transferases, two chemically close, but physiologically different amino acids are synthesized: symmetric and asymmetric dimethylarginine. The vascular origin of asymmetric dimethylarginine and its inhibitory activity on endothelial nitric oxide synthase give it an important role in certain diseases in which microcirculation is compromised: hypertension, atherosclerosis, inflammatory bowel disease, and diabetes. This review discusses the role that asymmetric dimethylarginine plays in the development of vascular disease, and, wherever possible, evaluates its use in clinical diagnosis. The fact that a number of chemically unrelated drugs, such as angiotensin II antagonists, selective beta- 1 adrenergic antagonists, plant phenolics, statins, and farnesoid X receptor agonists have all been found to reduce dimethylarginine levels in plasma or tissue allows for an integrated study. Although it is difficult to determine exactly why these various agents all have the same effect on arginine metabolism, an explanation of their mechanisms of action is needed. We have thus analyzed the mechanisms involved and reviewed potential trends in the therapeutic use of these drugs.
Keywords: Asymmetric dimethylarginine, cardiovascular diseases, nitric oxide, protein post translational modifications
Current Medicinal Chemistry
Title: Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Volume: 18 Issue: 5
Author(s): M. Marin and S. Manez
Affiliation:
Keywords: Asymmetric dimethylarginine, cardiovascular diseases, nitric oxide, protein post translational modifications
Abstract: The aim of this paper is to review the latest data on the pharmacological modulation of asymmetric dimethylarginine in human disease. When the terminal nitrogens of the guanidine portion of an arginine become methylated through the action of N-methyl transferases, two chemically close, but physiologically different amino acids are synthesized: symmetric and asymmetric dimethylarginine. The vascular origin of asymmetric dimethylarginine and its inhibitory activity on endothelial nitric oxide synthase give it an important role in certain diseases in which microcirculation is compromised: hypertension, atherosclerosis, inflammatory bowel disease, and diabetes. This review discusses the role that asymmetric dimethylarginine plays in the development of vascular disease, and, wherever possible, evaluates its use in clinical diagnosis. The fact that a number of chemically unrelated drugs, such as angiotensin II antagonists, selective beta- 1 adrenergic antagonists, plant phenolics, statins, and farnesoid X receptor agonists have all been found to reduce dimethylarginine levels in plasma or tissue allows for an integrated study. Although it is difficult to determine exactly why these various agents all have the same effect on arginine metabolism, an explanation of their mechanisms of action is needed. We have thus analyzed the mechanisms involved and reviewed potential trends in the therapeutic use of these drugs.
Export Options
About this article
Cite this article as:
Marin M. and Manez S., Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease, Current Medicinal Chemistry 2011; 18 (5) . https://dx.doi.org/10.2174/092986711794480087
DOI https://dx.doi.org/10.2174/092986711794480087 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dronedarone – A New Alternative for Management of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data
Current Vascular Pharmacology Meet Our Section Editor
Current Pharmaceutical Analysis Association of Thrombospondin-1 (N700S) and Thrombospond in-4 (A387P) Gene Polymorphisms with the Incidence of Acute Myocardial Infarction in Egyptians
Current Pharmaceutical Biotechnology Adrenomedullin and Oxidative Stress in Vascular Damage and Metabolic Disease
Current Hypertension Reviews PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
Current Drug Targets A Novel Biginelli-Like Reaction: An Efficient One-pot Synthesis of Spiro[oxindole-quinazoline/pyrimidine]ones
Letters in Organic Chemistry Transplacental Transfer of Antiretroviral Drugs and Newborn Birth Weight in HIV-Infected Pregnant Women
Current HIV Research Safety Limits of Antidepressant Use Plus Combinations: Focus on Cardiovascular Function
Current Drug Metabolism Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets Adrenergic Action in Breast Cancer
Current Cancer Therapy Reviews Comparative Study of Nutritional and Phytochemical Attributes of Andrographis paniculata, Bryophyllum pinnatum and Clitoria ternatea for Nutraceutical Applications
Current Nutrition & Food Science The Therapeutic Potential of Angiotensin-converting Enzyme and Angiotensin Receptor Inhibitors in the Treatment of Colorectal Cancer: Rational Strategies and Recent Progress
Current Pharmaceutical Design Cardiometabolic Risk Related to the Association of hypertriglyceridemia-Low HDLc
Current Pharmaceutical Design Common Variants for Heart Failure
Current Genomics Cardiovascular Effects of Endogenous Estrogen and Hormone Therapy
Current Vascular Pharmacology Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry